Southeast Asia Business

As an emerging economy with promising potential, the Southeast Asian market features relatively rapid economic development, a considerable demographic dividend, and a sound business atmosphere. Thus, the development of its healthcare industry has shown vigorous vitality. The Group has seized this market opportunity by establishing Rxilient Health, a new pharma focused on emerging markets in Southeast Asia. Additionally, the Group has acquired a manufacturing plant in Singapore through its associate company PharmaGend, thus achieving full coverage of “R&D, manufacturing, and commercialization” value chain. The Group implements a “Glocalization” strategy in the Southeast Asia, aiming to build a “bridgehead” for global pharmaceutical companies entering the Southeast Asian market and to provide local patients with quality and affordable treatment options.